US Stock MarketDetailed Quotes
GPCR Structure Therapeutics
- 27.060
- +0.080+0.30%
Close Jan 17 16:00 ET
- 27.390
- +0.330+1.22%
Post 20:01 ET
1.55BMarket Cap-14.01P/E (TTM)
27.450High26.500Low846.85KVolume27.150Open26.980Pre Close22.90MTurnover1.56%Turnover RatioLossP/E (Static)57.26MShares62.74052wk High1.73P/B1.47BFloat Cap23.50052wk Low--Dividend TTM54.21MShs Float75.017Historical High--Div YieldTTM3.52%Amplitude20.800Historical Low27.037Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Structure Therapeutics Stock Forum
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
No comment yet